PharmaCielo Ltd.
PCLOF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.39 | 0.05 | -0.24 | 0.05 |
| FCF Yield | -41.91% | 19.04% | -1.36% | -2.98% |
| EV / EBITDA | -76.96 | -73.07 | -29.40 | -79.28 |
| Quality | ||||
| ROIC | -40.23% | -8.37% | -9.10% | -4.39% |
| Gross Margin | -30.32% | 3.97% | 14.97% | 42.85% |
| Cash Conversion Ratio | 1.83 | -1.63 | 0.06 | 0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.08% | 3.40% | -8.16% | -13.13% |
| Free Cash Flow Growth | -263.05% | 1,733.68% | 75.71% | 29.12% |
| Safety | ||||
| Net Debt / EBITDA | -52.02 | -47.63 | -20.21 | -48.20 |
| Interest Coverage | -2.94 | -1.42 | -1.37 | -0.72 |
| Efficiency | ||||
| Inventory Turnover | 0.98 | 0.21 | 0.49 | 0.43 |
| Cash Conversion Cycle | -94.13 | -1,763.23 | -473.98 | -474.52 |